Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven Attia

Showing results (51-60 of 77) with videos related to

Pageof 8
Sort By:
BMC Cancer|December 13, 2022
Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trialPatrick Schöffski, Suzanne George, Michael C Heinrich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 24, 2019
Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic OsteosarcomaLara E Davis, Vanessa Bolejack, Christopher W Ryan, et al.
Investigational New Drugs|October 12, 2013
A phase I study of vorinostat in combination with bortezomib in patients with advanced malignanciesWilliam R Schelman, Anne M Traynor, Kyle D Holen, et al.
Cancer Chemotherapy and Pharmacology|October 9, 2008
Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignanciesSteven Attia, Sherry Morgan-Meadows, Kyle D Holen, et al.
Cancer|April 30, 2019
A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomasRobin L Jones, Sant P Chawla, Steven Attia, et al.
The Oncologist|July 27, 2021
Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS StudyJohn R Zalcberg, Michael C Heinrich, Suzanne George, et al.
Future Oncology (London, England)|April 15, 2021
Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcomaMrinal Gounder, Albiruni R Abdul Razak, Adrienne M Gilligan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2022
Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III TrialSebastian Bauer, Robin L Jones, Jean-Yves Blay, et al.
The Oncologist|July 24, 2020
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 StudyRichard F Riedel, Karla V Ballman, Yao Lu, et al.
Rare Tumors|October 5, 2017
Comprehensive Genomic Profiling of a Rare Thyroid Follicular Dendritic Cell SarcomaJaime I Davila, Jason S Starr, Steven Attia, et al.
Pageof 8

Showing results (51-60 of 77) with videos related to

Sort By:
Pageof 8
BMC Cancer|December 13, 2022
Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trialPatrick Schöffski, Suzanne George, Michael C Heinrich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 24, 2019
Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic OsteosarcomaLara E Davis, Vanessa Bolejack, Christopher W Ryan, et al.
Investigational New Drugs|October 12, 2013
A phase I study of vorinostat in combination with bortezomib in patients with advanced malignanciesWilliam R Schelman, Anne M Traynor, Kyle D Holen, et al.
Cancer Chemotherapy and Pharmacology|October 9, 2008
Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignanciesSteven Attia, Sherry Morgan-Meadows, Kyle D Holen, et al.
Cancer|April 30, 2019
A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomasRobin L Jones, Sant P Chawla, Steven Attia, et al.
The Oncologist|July 27, 2021
Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS StudyJohn R Zalcberg, Michael C Heinrich, Suzanne George, et al.
Future Oncology (London, England)|April 15, 2021
Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcomaMrinal Gounder, Albiruni R Abdul Razak, Adrienne M Gilligan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2022
Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III TrialSebastian Bauer, Robin L Jones, Jean-Yves Blay, et al.
The Oncologist|July 24, 2020
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 StudyRichard F Riedel, Karla V Ballman, Yao Lu, et al.
Rare Tumors|October 5, 2017
Comprehensive Genomic Profiling of a Rare Thyroid Follicular Dendritic Cell SarcomaJaime I Davila, Jason S Starr, Steven Attia, et al.
Pageof 8